Open Beta
TREN
MetriLume
TREN

US marketsACAD

SEC-sourced researchBeta

ACAD

ACADIA PHARMACEUTICALS INC

Company comparison ↗

Data passport

CIK
0001070494
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Sep 24, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 726,437,000.0000 USD; December 2024: 957,797,000.0000 USD; December 2025: 1,071,505,000.0000 USD1.1B USD0 USD0December 2023December 2024December 2025
ACAD · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023726,437,000.0000Feb 26, 2026
December 2024957,797,000.0000Feb 26, 2026
December 20251,071,505,000.0000Feb 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20251,071,505,000.0000391,000,000.0000109,836,000.00001,564,195,000.0000336,805,000.0000Feb 26, 2026
December 2024957,797,000.0000226,451,000.0000157,719,000.00001,187,756,000.0000454,963,000.0000Feb 26, 2026
December 2023726,437,000.0000-61,286,000.000016,702,000.0000——Feb 26, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

82/100
Profitability100
Growth62
Balance sheet78
Cash generation71
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$1.07BJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$957.8MJan 1, 2024 – Dec 31, 2024Feb 26, 202610-K
Net incomeNetIncomeLoss$391MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$109.84MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Total assetsAssets$1.56BDec 31, 2025Feb 26, 202610-K
Total liabilitiesLiabilities$336.81MDec 31, 2025Feb 26, 202610-K

New filings

Explore methodology ↗